TNFR1-TRPA1 pathway

The "TNFR1-TRPA1 pathway" informally denotes the interaction in which Tumor necrosis factor alpha (TNFα), acting through its receptor TNFR1 (Tumor necrosis factor receptor 1), modulates the trafficking and surface expression of the TRPA1 ion channel on sensory neurons[3][2][1]. TNFα, a pro-inflammatory cytokine, binds to TNFR1 and initiates complex intracellular signaling that can lead to inflammation, apoptosis, or survival responses depending on context[2]. In sensory neurons, TNFα stimulation increases the surface abundance of TRPA1 (and TRPV1), heightening neuronal responsiveness to painful or noxious stimuli. This process involves increased vesicular trafficking, mediated by SNARE proteins, and can be blocked by agents interfering with exocytosis[3]. However, "TNFR1-TRPA1 pathway" as a term does not correspond to a singular drug target but to a signaling interaction relevant to pain and inflammatory conditions. For therapeutic development or pharmacological targeting, TNFR1 and TRPA1 should be considered individually as distinct entities[1][2][3].

TRPA1 antagonists block cation influx through TRPA1, preventing nociceptor activation and pain transmission[1] - TNFα inhibitors neutralize TNFα, thus indirectly restricting TNFR1-initiated inflammatory signaling[2] - Botulinum toxins disrupt SNARE complex-dependent trafficking of TRPA1 to the plasma membrane, preventing channel upregulation and associated pain hypersensitivity[3]